Phenotypic analyses of circulating lymphocytes
. | . | . | Flow cytometry, % . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | Sézary cells, % . | Immunoscopy: Vβ family of T-cell clones . | Expanded TCR (Vβ) . | TCRαβ . | CD4 . | CD158k . | SC5 . | TCR Vβ and CD158k . | TCR Vβ and SC5 . | ||||||
| 1 | 30 | 17 | 38 (Vβ17) | 85 | 80 | 16 | 25 | 16 | 8 | ||||||
| 2 | 70 | 2 | 95 (Vβ2) | 90 | 90 | 80 | ND | 80 | ND | ||||||
| 3 | 70 | 3, 4, 8 | 85 (Vβ8) | 95 | 90 | 75 | 10 | 70 | 10 | ||||||
| 4 | 80 | 7 | 95 (Vβ7) | 90 | 95 | 85 | 55 | 85 | 53 | ||||||
| 5 | 80 | 3, 13, 16 | 20 (Vβ13.1) | 45 | 60 | 60 | 20 | 13 | 2 | ||||||
| 6 | 50 | 11 | 16 (Vβ11) | 56 | 60 | 18 | 70 | 15 | 11 | ||||||
| 7 | 95 | 8 | 92 (Vβ8) | 98 | 95 | 30 | 10 | 30 | 10 | ||||||
| 8 | 90 | 5, 17, 18 | 10 (Vβ17) | 90 | 95 | 65 | 35 | 0 | 5 | ||||||
| 9 | 10 | 14, 6 | 20 (Vβ14) | 65 | 47 | 8 | 36 | 0 | 10 | ||||||
| 10 | 80 | ND | ND | 95 | 95 | 70 | 23 | ND | ND | ||||||
| 10* | 0 | 14, 17, 20, 21 | 37 (Vβ14) | 95 | ND | 0 | 95 | 0 | 50 | ||||||
| 11 | 35 | 22 | 5 (Vβ22) | 45 | 65 | 25 | 15 | 0 | 5 | ||||||
| 11† | 0 | 22 | 3 (Vβ22) | 50 | 30 | 3 | 40 | ND | ND | ||||||
| 12 | 50 | 5, 15, 23 | None | 95 | 92 | 50 | 25 | ND | ND | ||||||
| 13 | 60 | 3, 15, 17, 23 | None | 80 | 80 | 15 | 34 | ND | ND | ||||||
. | . | . | Flow cytometry, % . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | Sézary cells, % . | Immunoscopy: Vβ family of T-cell clones . | Expanded TCR (Vβ) . | TCRαβ . | CD4 . | CD158k . | SC5 . | TCR Vβ and CD158k . | TCR Vβ and SC5 . | ||||||
| 1 | 30 | 17 | 38 (Vβ17) | 85 | 80 | 16 | 25 | 16 | 8 | ||||||
| 2 | 70 | 2 | 95 (Vβ2) | 90 | 90 | 80 | ND | 80 | ND | ||||||
| 3 | 70 | 3, 4, 8 | 85 (Vβ8) | 95 | 90 | 75 | 10 | 70 | 10 | ||||||
| 4 | 80 | 7 | 95 (Vβ7) | 90 | 95 | 85 | 55 | 85 | 53 | ||||||
| 5 | 80 | 3, 13, 16 | 20 (Vβ13.1) | 45 | 60 | 60 | 20 | 13 | 2 | ||||||
| 6 | 50 | 11 | 16 (Vβ11) | 56 | 60 | 18 | 70 | 15 | 11 | ||||||
| 7 | 95 | 8 | 92 (Vβ8) | 98 | 95 | 30 | 10 | 30 | 10 | ||||||
| 8 | 90 | 5, 17, 18 | 10 (Vβ17) | 90 | 95 | 65 | 35 | 0 | 5 | ||||||
| 9 | 10 | 14, 6 | 20 (Vβ14) | 65 | 47 | 8 | 36 | 0 | 10 | ||||||
| 10 | 80 | ND | ND | 95 | 95 | 70 | 23 | ND | ND | ||||||
| 10* | 0 | 14, 17, 20, 21 | 37 (Vβ14) | 95 | ND | 0 | 95 | 0 | 50 | ||||||
| 11 | 35 | 22 | 5 (Vβ22) | 45 | 65 | 25 | 15 | 0 | 5 | ||||||
| 11† | 0 | 22 | 3 (Vβ22) | 50 | 30 | 3 | 40 | ND | ND | ||||||
| 12 | 50 | 5, 15, 23 | None | 95 | 92 | 50 | 25 | ND | ND | ||||||
| 13 | 60 | 3, 15, 17, 23 | None | 80 | 80 | 15 | 34 | ND | ND | ||||||
The population of viable lymphocytes was gated according to morphologic criteria of forward and side scatter.
ND indicates not determined.
Data during the course of a treatment with anti-CD52 monoclonal antibodies (alemtuzumab).
Data at the time of clinical remission under treatment with extracorporeal photochemotherapy.